Skip to main content
Download PDF

Comprehensive analysis of ID genes reveals the clinical and prognostic value of ID3 expression in acute myeloid leukemia using bioinformatics identification and experimental validation

BMC Cancer volume 22, Article number: 1229 (2022) Cite this article

Abstract

Background

Dysregulation of inhibitor of differentiation/DNA binding (ID) genes is linked to cancer growth, angiogenesis, invasiveness, metastasis and patient survival. Nevertheless, few investigations have systematically determined the expression and prognostic value of ID genes in acute myeloid leukemia (AML).

Methods

The expression and clinical prognostic value of ID genes in AML were first identified by public databases and further validated by our research cohort.

Results

Using public data, the expression of ID1/ID3 was markedly downregulated in AML, and the expression of ID2 was greatly upregulated in AML, whereas ID4 showed no significant difference. Among the ID genes, only ID3 expression may be the most valuable prognostic biomarker in both total AML and cytogenetically normal AML (CN-AML) and especially in CN-AML. Clinically, reduced ID3 expression was greatly associated with higher white blood cell counts, peripheral blood/bone marrow blasts, normal karyotypes and intermediate cytogenetic risk. In addition, low ID3 expression was markedly related to FLT3 and NPM1 mutations as well as wild-type TP53. Despite these associations, multivariate Cox regression analysis revealed that ID3 expression was an independent risk factor affecting overall survival (OS) and disease free survival (DFS) in CN-AML patients. Biologically, a total of 839 mRNAs/lncRNAs and 72 microRNAs were found to be associated with ID3 expression in AML. Importantly, the expression of ID3 with discriminative value in AML was further confirmed in our research cohort.

Conclusion

The bioinformatics analysis and experimental verification demonstrate that low ID3 expression independently affects OS and DFS in patients with CN-AML, which might be seen as a potential prognostic indicator in CN-AML.

Peer Review reports

Background

Acute myeloid leukemia (AML) is a clonal disease characterized by amplification of immature myeloid progenitors with differentiation arrest in the bone marrow (BM), finally resulting in hematopoietic failure [1]. AML is a clinically, cytogenetically and molecularly heterogeneous disease with variable clinical outcomes [1]. The features of morphology, immunology, cytogenetics and molecular biology (MICM) are the basis for AML diagnosis [1]. Cytogenetic abnormalities also provide the most important prognostic information of AML [2]. Molecular biological alterations, such as gene mutations and aberrant gene expression, also play important roles in leukemogenesis and predict treatment response and patient survival [2]. Therefore, the identification of biological markers to develop a better prognostic, diagnostic and therapeutic risk stratification for AML is of great importance.

The inhibitor of differentiation/DNA binding (ID) genes (ID1/ID2/ID3/ID4) encode ID proteins that are transcriptional regulators controlling the timing of cell fate determination and differentiation in stem and progenitor cells during physiological development [3, 4]. It was suggested that ID proteins could have key roles in cancer development [3, 4]. At the same time, dysregulated ID gene expression was linked to tumor growth, invasiveness, metastasis, angiogenesis and patient survival [3, 4]. ID1 and ID2 overexpression has been shown to correlate with enhanced malignant potential in various types of cancers including AML [3, 4]. Although increased ID1 expression was observed in AML patients, the prognostic value of ID1 overexpression remains controversial [5,6,7]. In addition, the prognostic effect of ID2 overexpression in AML was reported in our previous study [8]. In contrast, ID4 functioned as a tumor suppressor presenting a paradigm shift in the context of ID1 and ID2 during the process of tumorigenesis and leukemogenesis [3]. ID4 hypermethylation was an independent factor that affected clinical outcome and predicted leukemic transformation in patients with myelodysplastic syndrome (MDS) [9]. However, the function of ID3 and its expression pattern in AML are not completely understood. Herein, we systematically explored the expression and clinical implications of ID genes expression in AML.

Materials and methods

Patients from public datasets and our hospital

The identification cohort included 173 AML patients with ID gene (ID1/ID2/ID3/ID4) expression data (RNA-Seq V2 data) from public The Cancer Genome Atlas (TCGA) datasets [10]. All AML patients received standard chemotherapy as induction therapy. Following induction therapy, 100 patients underwent chemotherapy only, whereas the remaining 73 patients underwent auto/allo-hematopoietic stem cell transplantation as consolidation treatment. The ID gene expression in AML compared with controls was analyzed by GEPIA [11].

The validation cohort contained 107 AML patients treated at the Affiliated People’s Hospital of Jiangsu University. Patients with antecedent hematological diseases or therapy-related AML were excluded. The clinical characteristics of the AML patients are shown in Supplementary Table S1. BM samples were collected from AML patients once they were diagnosed. A total of 32 healthy donors served as normal controls. The age of the AML patients (median 57, range 18–87) showed no significant differences from that of the controls (median 52, range 20–66) (P > 0.05). This current study was approved by the Ethics Committee of the Affiliated People’s Hospital of Jiangsu University, and all the individuals provided written informed consent.

RNA isolation and reverse transcription

BM mononuclear cells (BMMNCs) were separated through gradient centrifugation using Lymphocyte Separation Medium (Solarbio, Beijing, China), and then used for total RNA extraction by TRIzol reagent (Invitrogen, Carlsbad, CA). Reverse transcription was performed to synthesize cDNA as reported [12,13,14].

RT–qPCR

The detection of ID3 and ABL1 (housekeeping gene) mRNA was determined by real-time quantitative PCR (RT–qPCR) using AceQ qPCR SYBR Green Master Mix (Vazyme, Piscataway, NJ). The primers applied for ID3 expression detection were 5’-ACTCAGCTTAGCCAGGTGGA-3’ (forward) and 5’-AAGCTCCTTTTGTCGTTGGA-3’ (reverse), whereas those for ABL1 expression detection were 5’-TCCTCCAGCTGTTATCTGGAAGA-3’ (forward) and 5’-TCCAACGAGCGGCTTCAC-3’ (reverse). The relative ID3 mRNA level was measured according to the 2−∆∆Ct method [12,13,14].

Bioinformatics analysis

All procedures regarding the bioinformatics analysis were carried out as described in our previous studies [15, 16]. To obtain the differentially expressed genes/miRNAs (DEGs/DEmiRs), analysis of the RNA sequencing data was conducted based on the raw read counts with the R/Bioconductor package “edgeR”. All statistical analyses were controlled for the false discovery rate (FDR) by the Benjamini–Hochberg procedure.

Statistical analysis

Statistical analysis was carried out based on the SPSS 20.0 and GraphPad 5.0 software. Comparisons of continuous and categorical variables were conducted using the Mann–Whitney U test/Kruskal–Wallis test and Pearson’s χ2 test/Fisher’s exact test, respectively. Kaplan–Meier analysis (log-rank test) and Cox regression (proportional hazards model, backward method) were used to analyze the effect of ID1/ID2/ID3/ID4 expression on survival including disease-free survival (DFS) and overall survival (OS). The ability of ID3 expression to discriminate in AML patients from controls was evaluated by the receiver operating characteristic (ROC) curve and area under the ROC curve (AUC). A two-sided P value less than 0.05 was considered statistically significant in all analyses.

Results

Identification of reduced ID3 expression among ID genes correlated with prognosis in AML from public TCGA datasets

We first searched GEPIA to determine the expression of ID genes (ID1/ID2/ID3/ID4) in AML. As presented in Fig. 1, the expression of ID1 and ID3 was markedly downregulated (both P < 0.001), and the expression of ID2 was greatly upregulated in AML (P < 0.001), whereas ID4 showed no dramatic difference in expression (P > 0.05).

Fig. 1 
figure 1

Expression of ID genes in AML. a ID1 expression in AML; b ID2 expression in AML; c ID3 expression in AML; d ID4 expression in AML. *: P < 0.001. The expression of ID genes expression in AML compared with controls is analyzed in GEPIA (http://gepia.cancer-pku.cn/)

Full size image

Next, to investigate the prognostic significance of the ID genes in AML, we evaluated the impact of ID gene expression on OS and DFS times by Kaplan–Meier analysis. When analyzing the prognostic value, the AML patients were divided into two groups by the median level of ID gene expression. In all the AML patients, only high ID2 expression was markedly associated with a shorter OS time (P = 0.023), whereas the other ID members did not affect either OS or DFS time (P > 0.05) (Fig. 2). In cytogenetically normal AML (CN-AML) patients, lower ID3 and ID4 expression was nearly or markedly correlated with shorter OS (P = 0.027 and 0.034, respectively) and DFS (P = 0.037 and 0.056, respectively), whereas the other ID members did not affect either OS or DFS times (P > 0.05) (Fig. 2).

Fig. 2
figure 2

Prognostic value of ID genes in AML. The prognostic effect of ID genes (ID1/ID2/ID3/ID4) on overall survival and disease free survival were analyzed by Kaplan–Meier method

Full size image

Finally, we further investigated the impact of ID gene expression on OS and DFS times in AML by Cox regression analysis. In all the AML patients, the expression of ID1, ID2 and ID3 independently affected the OS time (P = 0.016, 0.039 and 0.028, respectively) (Table 1), whereas the expression of ID1 and ID3 independently affected the DFS time (P = 0.043 and 0.022, respectively) (Supplementary Table S2). Among CN-AML patients, only ID3 expression independently affected both the OS and DFS times (P = 0.030 and 0.041, respectively) (Table 1 and Supplementary Table S2).

Table 1 Cox regression univariate and multivariate analysis of variables for overall survival in AML patients
Full size table

Taken together, these results suggest that ID3 expression may be most valuable prognostic biomarker among the ID genes in AML, especially CN-AML, and it was selected for further analysis.

Clinical significance of ID3 expression and its correlation with gene mutations in AML

To further analyze the clinical relevance of ID3 expression in AML, the AML patients from TCGA dataset were divided into two groups by the median ID3 expression level. Comparisons of clinicopathological features, including age, sex, white blood cell (WBC) count, peripheral blood (PB)/BM blasts, French–American–British (FAB) classifications, cytogenetics and gene mutations, between the two groups (low and high ID3 expression) in both the total AML and the CN-AML cohort are shown in Table 2. In all AML patients, low ID3 expression was greatly correlated with higher WBC counts and PB/BM blasts (P < 0.001, = 0.001 and = 0.002, respectively). Moreover, low ID3 expression was markedly correlated with normal karyotype and intermediate cytogenetic risk (P = 0.004 and 0.014, respectively). Based on the results, we further compared ID3 expression between AML patients with different cytogenetic risks, and confirmed the significant differences (P = 0.036, Fig. 3a). In addition, low ID3 expression was markedly associated with FLT3 and NPM1 mutations as well as wild-type TP53 (P = 0.018, 0.011 and 0.028, respectively). Similarly, we further determined ID3 expression between AML patients with and without these gene mutations. Expectedly, marked differences were observed in subgroups divided by FLT3 and NPM1 status (P = 0.005 and 0.003, respectively, Fig. 3b-c), whereas a trend was observed in subgroups divided by TP53 and CEBPA status (P = 0.063 and 0.088, respectively, Fig. 3d-e). In CN-AML, the above significant differences were not observed (Table 2).

Fig. 3
figure 3

The associations of ID3 expression with cytogenetic risks/genetic abnormalities in AML. a ID3 expression among different cytogenetic risks of AML. b ID3 expression in AML patients with and without FLT3 mutations. c ID3 expression in AML patients with and without NPM1 mutations. d ID3 expression in AML patients with and without CEBPA mutations. e ID3 expression in AML patients with and without TP53 mutations

Full size image
Table 2 Correlation of ID3 expression with clinic-pathologic characteristics in AML patients
Full size table

The independent prognostic value of ID3 expression in AML

Because a marked correlation was found between ID3 expression and common prognostic factors such as WBC, cytogenetics and gene mutations, we performed multivariate analysis by Cox regression to confirm the independent prognostic impact of ID3 expression in AML after adjusting for the prognosis-related factors. Multivariate Cox regression analysis indicated that ID3 expression was an independent risk factor affecting OS (P = 0.022, Table 3) and DFS (P = 0.043 and Supplementary Table S3) in CN-AML patients.

Table 3 Cox regression multivariate analysis of variables for overall survival in AML patients
Full size table

Molecular signatures correlated with ID3 expression in AML

To investigate the biological network caused by aberrant ID3 expression in AML, we first analyzed the transcriptomes of the two groups of patients (low and high ID3 expression) from the TCGA dataset. Based on the conditions of |log2 FC|>1.5, FDR < 0.05 and P < 0.05, a total of 839 DEGs (706 downregulated and 133 upregulated) between the low and high ID3 expression groups were identified (Fig. 4a-b and Supplementary Table S4). The top 100 downregulated DEGs, such as SLIT3 and ID4, are reported to have antitumor activities in AML [9, 17, 18]. Moreover, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses [19,20,21] revealed that these DEGs are involved in multiple biological processes and the PI3K/AKT signaling pathway (Fig. 4c-d).

Fig. 4
figure 4

Biological network of aberrant ID3 expression in AML. a Expression heatmap of differentially expressed mRNAs/lncRNAs between low and high ID3 expression groups in AML (|log2 FC|>1.5, FDR < 0.05 and P < 0.05). b Volcano plot of differentially expressed mRNAs/lncRNAs between low and high ID3 expression groups in AML. c Gene Ontology (GO) analysis of differentially expressed mRNAs/lncRNAs. d Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of differentially expressed mRNAs/lncRNAs. e Expression heatmap of differentially expressed miRNAs between low and high ID3 expression groups in AML (FDR < 0.05 and P < 0.05)

Full size image

We next revealed 72 DEmiRs (38 downregulated and 34 upregulated) between the low and high ID3 expression groups according to the conditions of FDR < 0.05 and P < 0.05) (Fig. 4e and Supplementary Table S4). The top 10 downregulated DEmiRs, including miR-139, miR-195, miR-203, miR-497 and miR-144, are reported to have antitumor effects in AML [22,23,24,25,26]. The top 10 upregulated DEmiRs, such as miR-196a, are reported to have protumor effects in AML [27]. Moreover, upregulated DEmiRs (potentially negatively associated with ID3 expression), such as miR-326, have been reported as potential microRNAs that directly target ID3 [28].

Validation of ID3 expression and its discriminative capacity in AML patients from our hospital

Given the results above, we further validated the expression of ID3 in the BMMNC samples of 107 newly diagnosed AML patients and 32 healthy donors as normal controls from our hospital. The expression of ID3 was extremely decreased in AML patients compared with normal controls (P = 0.001, Fig. 5a). Moreover, ROC analysis indicated that ID3 expression may serve as a prospective biomarker for discriminating AML patients from controls, with an AUC of 0.701 (95% CI: 0.598–0.805) (P = 0.001, Fig. 5b). These results confirmed the low expression pattern of ID3 in AML and revealed that ID3 expression might serve as a latent biomarker that is helpful for the diagnosis of AML.

Fig. 5
figure 5

Validation of ID3 expression and its discriminative capacity in AML. a The relative expression of ID3 in AML. b ROC curve analysis of ID3 expression in distinguishing AML controls

Full size image

Discussion

Dysregulation of ID gene expression has been revealed in various human cancers including AML, and was also associated with clinical outcome. Recently, Lu et al. using bioinformatics methods revealed that increased expression of ID1 and ID2 was correlated with poorer and better survival times, respectively, whereas ID3 and ID4 expression was not correlated with survival in lung adenocarcinoma patients [29]. Similarly, abnormal expression of ID genes may affect the occurrence and prognosis of lung cancer, and may be associated with cell metabolism and transcriptional regulation by using bioinformatics analysis [30]. These same results were further identified in breast cancer [31]. In the current study, by the bioinformatics analysis, we found that the expression of ID1 and ID3 was downregulated in AML, whereas the expression of ID2 was upregulated. Moreover, only abnormal ID3 expression may serve as an independent prognostic biomarker in AML and ID1/ID2 expression may independently affect clinical outcome in total AML. Previously, a few studies have reported the prognostic significance of ID gene expression in AML. Tang et al. revealed that high ID1 expression was correlated with adverse prognosis in AML [5]. However, a later study demonstrated that overexpression of ID1 was not an independent prognostic biomarker in young CN-AML patients [6]. Interestingly, our previous study indicated that overexpression of ID1 was correlated with higher karyotypic risk classification and served as an independent risk factor in young (age < 60 years) non-M3 patients [7]. Meanwhile, overexpression of ID2 was a frequent event in patients with AML and predicted poor chemotherapy response and clinical outcome [8]. Conversely, promoter hypermethylation-mediated ID4 repression was linked to disease progression in MDS and poor prognosis in AML. Altogether, these different results may be attributed to the differences in ethnicity and in AML subtype distribution. Accordingly, further studies are needed to validate the expression and clinical implications of the ID genes in AML.

In the present study, we mainly focused on ID3 expression in AML based on the bioinformatics identification and experimental validation. For the first time, we revealed that ID3 expression could serve as a prognostic predictor in AML. Notably, it is very interesting that ID3 could independently affect OS but not DFS by multivariate Cox regression analysis. We deduced that the role of aberrant ID3 expression in AML survival was not directly mediated by influencing leukemia development but could affect multiple factors that lead to all-cause death in AML. Previously, only May et al. revealed that ID2 and ID3 protein expression mirrored granulopoietic maturation and discriminated between acute leukemia subtypes [32]. However, numerous studies have investigated the expression and prognostic value of ID3 in human solid tumors. Xu et al. demonstrated that ID3 played a tumor suppressive role in papillary thyroid cancer and impeded metastasis by inhibiting E47-mediated epithelial to mesenchymal transition (EMT) [33]. Huang et al. indicated that ID3 could enhance the stemness of intrahepatic cholangiocarcinoma by gaining the transcriptional activity of β-catenin and could act as a potential biomarker in predicting response to adjuvant chemotherapeutics [34]. Moreover, ID3 overexpression was correlated with medulloblastoma seeding and is a poor prognostic factor in medulloblastoma patients [35]. Sharma et al. revealed that ID1 and ID3 overexpression alleviated all three cyclin-dependent kinase inhibitors (CDKN2B, -1 A, and − 1B) resulting in a more aggressive prostate cancer phenotype [36]. Expression of ID1 and ID3 was increased in human invasive lobular carcinoma compared with invasive ductal carcinoma, associated with poor prognosis uniquely in patients with invasive lobular carcinoma and correlated with the upregulation of angiogenesis and matrisome-related genes [37]. In addition to the above results, several studies have also reported the value of the combination of ID3 expression with other members in cancer prognosis. For instance, Antonângelo et al. showed that ID1, ID2 and ID3 coexpression was associated with prognosis in stage I/II lung adenocarcinoma patients treated with surgery and adjuvant chemotherapy [38]. Additionally, ID1 and ID3 coexpression was correlated with a poor clinical outcome in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy [39]. The combined expression of VPREB3 and ID3 was used to develop a new helpful tool for the routine diagnosis of mature aggressive B-cell lymphomas [40]. All these results suggested the prognostic value of ID3 expression in diverse human cancers.

The functional role of ID3 has also been widely investigated, and was reported to be associated with diverse biological processes such as angiogenesis, apoptosis, cell cycle regulation/proliferation, cell migration/invasion, epithelial-to-mesenchymal transition, stem cell renewal and signaling [3]. Although we did not validate the direct role of ID3 in AML in this study, we identified the association of ID3 with PI3K/AKT signaling by bioinformatics methods. Moreover, the association of low ID3 expression with FLT3 mutation was also observed in AML patients. Similarly, Chen et al. demonstrated that miR-212-5p was involved in the progression of non-small cell lung cancer through the activation of PI3K/Akt signaling pathway by targeting ID3 [41]. Zhang et al. indicated that Per2 downregulated ID3 expression via the PTEN/AKT/Smad5 axis to inhibit glioma cell proliferation [42]. Moreover, ID3 was reported to play a significant role in reversing cisplatin resistance in human lung adenocarcinoma cells by regulating the PI3K/Akt pathway [43]. Accordingly, further functional studies are needed to confirm the direct role of ID3 in AML biology.

The regulatory mechanism of ID3 expression was preliminarily studied. Xu et al. demonstrated that hypermethylation of the CpG island at the promoter region of ID3 was the main contributor to the repression of this gene [33]. In addition, several studies also revealed the regulatory potential of miRNAs. Zhao et al. found that miR-326 could bind to ID3, which accelerated the development of medulloblastoma [28]. Moreover, high ID3 expression by silencing miR-212-5p expression suppressed the activity of the PI3K/Akt signaling pathway and consequently promoted apoptosis and inhibited proliferation in lung cancer cells [41]. Herein, we also observed the association of ID3 with several miRNAs such as miR-1259, miR-508, miR-9, miR-944, let-7b, miR-141, and miR-223. However, only miR-326 was confirmed by previous studies [28]. Accordingly, further studies are needed to confirm the direct association of ID3 with these miRNAs.

Conclusion

In summary, the bioinformatics analysis and experimental verification demonstrate that low ID3 expression independently affects OS and DFS in patients with CN-AML, which might be seen as a potential prognostic indicator in CN-AML.

Availability of data and materials

The datasets analyzed in this study are available in the following open access repositories: cBioPortal (http://www.cbioportal.org/); TCGA (https://portal.gdc.cancer.gov/) and GEPIA (http://gepia.cancer-pku.cn/).

Abbreviations

ID:

Inhibitor of Differentiation/DNA binding

AML:

Acute myeloid leukemia

CN-AML:

Cytogenetically normal AML

BM:

Bone marrow

MICM:

Morphology, immunology, cytogenetics and molecular biology

TCGA:

The Cancer Genome Atlas

BMMNCs:

BM mononuclear cells

FDR:

False discovery rate

DFS:

Disease-free survival

OS:

Overall survival

AUC:

Area under the ROC curve

ROC:

Receiver operating characteristic

WBC:

White blood cell

PB:

Peripheral blood

FAB:

French–American–British

DEGs/DEmiRs:

Differentially expressed genes/miRNAs

GO:

Gene Ontology

KEGG:

Kyoto Encyclopedia of Genes and Genomes

EMT:

Epithelial to mesenchymal transition

References

  1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–52.

    Article  PubMed  Google Scholar 

  2. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Lasorella A, Benezra R, Iavarone A. The ID proteins: master regulators of cancer stem cells and tumour aggressiveness. Nat Rev Cancer. 2014;14(2):77–91.

    Article  CAS  PubMed  Google Scholar 

  4. Roschger C, Cabrele C. The Id-protein family in developmental and cancer-associated pathways. Cell Commun Signal. 2017;15(1):7.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Tang R, Hirsch P, Fava F, Lapusan S, Marzac C, Teyssandier I, Pardo J, Marie JP, Legrand O. High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia. Blood. 2009;114(14):2993–3000.

    Article  CAS  PubMed  Google Scholar 

  6. Damm F, Wagner K, Görlich K, Morgan M, Thol F, Yun H, Delwel R, Valk PJM, Löwenberg B, Heuser M, Ganser A, Krauter J. ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia. Br J Haematol. 2012;158(2):208–15.

    Article  CAS  PubMed  Google Scholar 

  7. Zhou JD, Yang L, Zhu XW, Wen XM, Yang J, Guo H, Chen Q, Yao DM, Ma JC, Lin J, Qian J. Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemia. Int J Clin Exp Pathol. 2015;8(5):5336–44.

    PubMed  PubMed Central  Google Scholar 

  8. Zhou JD, Ma JC, Zhang TJ, Li XX, Zhang W, Wu DH, Wen XM, Xu ZJ, Lin J, Qian J. High bone marrow ID2 expression predicts poor chemotherapy response and prognosis in acute myeloid leukemia. Oncotarget. 2017;8(54):91979–89.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Zhou JD, Zhang TJ, Li XX, Ma JC, Guo H, Wen XM, Zhang W, Yang L, Yan Y, Lin J, Qian J. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies. J Cell Mol Med. 2017;21(8):1468–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ Jr, Laird PW, Baty JD, Fulton LL, Fulton R, Heath SE, Kalicki-Veizer J, Kandoth C, Klco JM, Koboldt DC, Kanchi KL, Kulkarni S, Lamprecht TL, Larson DE, Lin L, Lu C, McLellan MD, McMichael JF, Payton J, Schmidt H, Spencer DH, Tomasson MH, Wallis JW, Wartman LD, Watson MA, Welch J, Wendl MC, Ally A, Balasundaram M, Birol I, Butterfield Y, Chiu R, Chu A, Chuah E, Chun HJ, Corbett R, Dhalla N, Guin R, He A, Hirst C, Hirst M, Holt RA, Jones S, Karsan A, Lee D, Li HI, Marra MA, Mayo M, Moore RA, Mungall K, Parker J, Pleasance E, Plettner P, Schein J, Stoll D, Swanson L, Tam A, Thiessen N, Varhol R, Wye N, Zhao Y, Gabriel S, Getz G, Sougnez C, Zou L, Leiserson MD, Vandin F, Wu HT, Applebaum F, Baylin SB, Akbani R, Broom BM, Chen K, Motter TC, Nguyen K, Weinstein JN, Zhang N, Ferguson ML, Adams C, Black A, Bowen J, Gastier-Foster J, Grossman T, Lichtenberg T, Wise L, Davidsen T, Demchok JA, Shaw KR, Sheth M, Sofia HJ, Yang L, Downing JR, Eley G. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–74.

    Article  Google Scholar 

  11. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Zhang TJ, Xu ZJ, Gu Y, Wen XM, Ma JC, Zhang W, Deng ZQ, Leng JY, Qian J, Lin J, Zhou JD. Identification and validation of prognosis-related DLX5 methylation as an epigenetic driver in myeloid neoplasms. Clin Transl Med. 2020;10(2):e29.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Zhou JD, Zhang TJ, Xu ZJ, Deng ZQ, Gu Y, Ma JC, Wen XM, Leng JY, Lin J, Chen SN, Qian J. Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes. Cell Death Dis. 2020;11(11):997.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zhang TJ, Xu ZJ, Gu Y, Ma JC, Wen XM, Zhang W, Deng ZQ, Qian J, Lin J, Zhou JD. Identification and validation of obesity-related gene LEP methylation as a prognostic indicator in patients with acute myeloid leukemia. Clin Epigenetics. 2021;13(1):16.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Xu ZJ, Ma JC, Zhou JD, Wen XM, Yao DM, Zhang W, Ji RB, Wu DH, Tang LJ, Deng ZQ, Qian J, Lin J. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia. J Transl Med. 2019;17(1):102.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Gu Y, Chu MQ, Xu ZJ, Yuan Q, Zhang TJ, Lin J, Zhou JD. Comprehensive analysis of SPAG1 expression as a prognostic and predictive biomarker in acute myeloid leukemia by integrative bioinformatics and clinical validation. BMC Med Genomics. 2022;15(1):38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Shi L, Huang Y, Huang X, Zhou W, Wei J, Deng D, Lai Y. Analyzing the key gene expression and prognostics values for acute myeloid leukemia. Transl Cancer Res. 2020;9(11):7284–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Zhou JD, Li XX, Zhang TJ, Xu ZJ, Zhang ZH, Gu Y, Wen XM, Zhang W, Ji RB, Deng ZQ, Lin J, Qian J. MicroRNA-335/ID4 dysregulation predicts clinical outcome and facilitates leukemogenesis by activating PI3K/Akt signaling pathway in acute myeloid leukemia. Aging. 2019;11(10):3376–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545–51.

    Article  CAS  PubMed  Google Scholar 

  22. Stavast CJ, van Zuijen I, Karkoulia E, Özçelik A, van Hoven-Beijen A, Leon LG, Voerman JSA, Janssen GMC, van Veelen PA, Burocziova M, Brouwer RWW, van IJcken WFJ, Maas A, Bindels EM, van der Velden VHJ, Schliehe C, Katsikis PD, Alberich-Jorda M, Erkeland SJ. The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis. Leukemia. 2022;36(3):687–700.

    Article  CAS  PubMed  Google Scholar 

  23. Cui L, Zeng T, Zhang L, Liu Y, Wu G, Fu L. High expression of miR-195 is related to favorable prognosis in cytogenetically normal acute myeloid leukemia. Int J Clin Oncol. 2021;26(10):1986–93.

    Article  CAS  PubMed  Google Scholar 

  24. Zhang Y, Zhou SY, Yan HZ, Xu DD, Chen HX, Wang XY, Wang X, Liu YT, Zhang L, Wang S, Zhou PJ, Fu WY, Ruan BB, Ma DL, Wang Y, Liu QY, Ren Z, Liu Z, Zhang R, Wang YF. miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1. Sci Rep. 2016;6:19995.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Kang H, Tong C, Li C, Luo J. miR-497 plays a key role in Tanshinone IIA-attenuated proliferation in OCI-AML3 cells via the MAPK/ERK1/2 pathway. Cytotechnology. 2020;72(3);427–32.

  26. Sun X, Liu D, Xue Y, Hu X. Enforced mir-144-3p expression as a non-invasive biomarker for the Acute myeloid leukemia patients mainly by targeting NRF2. Clin Lab. 2017;63:679–87.

    Article  CAS  PubMed  Google Scholar 

  27. Coskun E, von der Heide EK, Schlee C, Kühnl A, Gökbuget N, Hoelzer D, Hofmann WK, Thiel E, Baldus CD. The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia. Leuk Res. 2011;35:208–13.

    Article  CAS  PubMed  Google Scholar 

  28. Zhao X, Guan J, Luo M. Circ-SKA3 upregulates ID3 expression by decoying miR-326 to accelerate the development of medulloblastoma. J Clin Neurosci. 2021;86:87–96.

    Article  CAS  PubMed  Google Scholar 

  29. Lu X, Shao L, Qian Y, Zhang Y, Wang Y, Miao L, Zhuang Z. Prognostic effects of the expression of inhibitor of DNA-binding family members on patients with lung adenocarcinoma. Oncol Lett. 2020;20(5):143.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Xu S, Wang Y, Li Y, Zhang L, Wang C, Wu X. Comprehensive analysis of inhibitor of differentiation/DNA-binding gene family in lung cancer using bioinformatics methods. Biosci Rep. 2020;40(2):BSR20193075.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Zhou XL, Zeng D, Ye YH, Sun SM, Lu XF, Liang WQ, Chen CF, Lin HY. Prognostic values of the inhibitor of DNA-binding family members in breast cancer. Oncol Rep. 2018;40(4):1897–906.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. May AM, Frey AV, Bogatyreva L, Benkisser-Petersen M, Hauschke D, Lübbert M, Wäsch R, Werner M, Hasskarl J, Lassmann S. ID2 and ID3 protein expression mirrors granulopoietic maturation and discriminates between acute leukemia subtypes. Histochem Cell Biol. 2014;141(4):431–40.

    Article  CAS  PubMed  Google Scholar 

  33. Xu S, Mo C, Lin J, Yan Y, Liu X, Wu K, Zhang H, Zhu Y, Chen L, Chen X. Loss of ID3 drives papillary thyroid cancer metastasis by targeting E47-mediated epithelial to mesenchymal transition. Cell Death Discov. 2021;7(1):226.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Huang L, Cai J, Guo H, Gu J, Tong Y, Qiu B, Wang C, Li M, Xia L, Zhang J, Wu H, Kong X, Xia Q. ID3 promotes stem cell features and predicts chemotherapeutic response of Intrahepatic Cholangiocarcinoma. Hepatology. 2019;69(5):1995–2012.

    Article  CAS  PubMed  Google Scholar 

  35. Chen M, Huang J, Zhu Z, Zhang J, Li K. Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer. BMC Cancer. 2013;13:291.

    Article  CAS  Google Scholar 

  36. Sharma P, Patel D, Chaudhary J. Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1B. Cancer Med. 2012;1(2):187–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Tasdemir N, Ding K, Savariau L, Levine KM, Du T, Elangovan A, Bossart EA, Lee AV, Davidson NE, Oesterreich S. Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma. Sci Rep. 2020;10(1):11487.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Antonângelo L, Tuma T, Fabro A, Acencio M, Terra R, Parra E, Vargas F, Takagaki T, Capelozzi V. Id-1, Id-2, and Id-3 co-expression correlates with prognosis in stage I and II lung adenocarcinoma patients treated with surgery and adjuvant chemotherapy. Exp Biol Med. 2016;241(11):1159–68.

    Article  Google Scholar 

  39. Castañon E, Bosch-Barrera J, López I, Collado V, Moreno M, López-Picazo JM, Arbea L, Lozano MD, Calvo A, Gil-Bazo I. Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy. J Transl Med. 2013;11:13.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Soldini D, Georgis A, Montagna C, Schüffler PJ, Martin V, Curioni-Fontecedro A, Martinez A, Tinguely M. The combined expression of VPREB3 and ID3 represents a new helpful tool for the routine diagnosis of mature aggressive B-cell lymphomas. Hematol Oncol. 2014;32(3):120–5.

    Article  CAS  PubMed  Google Scholar 

  41. Chen FF, Sun N, Wang Y, Xi HY, Yang Y, Yu BZ, Li XJ. Mir-212-5p exerts tumor promoter function by regulating the Id3/PI3K/Akt axis in lung adenocarcinoma cells. J Cell Physiol. 2020;235(10):7273–82.

    Article  CAS  PubMed  Google Scholar 

  42. Zhang Y, Hu X, Li H, Yao J, Yang P, Lan Y, Xia H. Circadian period 2 (Per2) downregulate inhibitor of differentiation 3 (Id3) expression via PTEN/AKT/Smad5 axis to inhibits glioma cell proliferation. Bioengineered. 2022;13(5):12350–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Chen FF, Lv X, Zhao QF, Xu YZ, Song SS, Yu W, Li XJ. Inhibitor of DNA binding 3 reverses cisplatin resistance in human lung adenocarcinoma cells by regulating the PI3K/Akt pathway. Oncol Lett. 2018;16(2):1634–40.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

None.

Funding

The work was supported by National Natural Science Foundation of China (81900166, 82100183), Natural Science Foundation of Jiangsu Province (BK20221287), Research Project of Jiangsu Commission of Health (M2022123), Social Development Foundation of Zhenjiang (SH2020055), Medical Field of Zhenjiang “Jin Shan Ying Cai” Project, Medical Education Collaborative Innovation Fund of Jiangsu University (JDY2022011).

Author information

Author notes

  1. Qi Zhao, Yun Wang and Di Yu contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology, Affiliated People’s Hospital of Jiangsu University, 8 Dianli Rd, 212002, Zhenjiang, Jiangsu, P. R. China

    Qi Zhao, Yun Wang, Di Yu, Jia-Yan Leng & Jingdong Zhou

  2. Zhenjiang Clinical Research Center of Hematology, 212002, Zhenjiang, Jiangsu, P. R. China

    Qi Zhao, Yun Wang, Di Yu, Jia-Yan Leng, Mingqiang Chu, Zijun Xu, Jingdong Zhou & Tingjuan Zhang

  3. The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Jiangsu, 212002, Zhenjiang, P. R. China

    Qi Zhao, Yun Wang, Di Yu, Jia-Yan Leng, Mingqiang Chu, Zijun Xu, Jingdong Zhou & Tingjuan Zhang

  4. Laboratory Center, Affiliated People’s Hospital of Jiangsu University, 212002, Zhenjiang, Jiangsu, P. R. China

    Qi Zhao, Mingqiang Chu & Zijun Xu

  5. Department of Respiratory Disease, Affiliated People’s Hospital of Jiangsu University, 8 Dianli Rd, 212002, Zhenjiang, Jiangsu, P. R. China

    Qi Zhao, Mingqiang Chu & Hao Ding

  6. Department of Laboratory Medicine, School of Medicine, Jiangsu University, 212013, Zhenjiang, Jiangsu, P. R. China

    Yangjing Zhao

  7. Department of Oncology, Affiliated People’s Hospital of Jiangsu University, 8 Dianli Rd, 212002, Zhenjiang, Jiangsu, P. R. China

    Tingjuan Zhang

Authors
  1. Qi Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Di Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jia-Yan Leng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yangjing Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mingqiang Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zijun Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hao Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jingdong Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tingjuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Jingdong Zhou and Tingjuan Zhang conceived and designed the experiments; Jingdong Zhou and Tingjuan Zhang performed the experiments; Qi Zhao, Yun Wang and Zijun Xu analyzed the data; Di Yu and Jiayan Leng collected the clinical data; Hao Ding and Yangjing Zhao provided the technical support; Jingdong Zhou and Tingjuan Zhang wrote the paper; All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Hao Ding, Jingdong Zhou or Tingjuan Zhang.

Ethics declarations

Ethics approval and consent to participate

The present study approved by the Ethics Committee of the Affiliated People’s Hospital of Jiangsu University, in compliance with the Declaration of Helsinki. Written informed consents were obtained from all enrolled individuals prior to their participation.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

 Table S1. Clinic-pathologic characteristics of AML in our research cohort.

Additional file 2

: Table S2. Cox regression univariate and multivariate analysis of variables for disease free survival in AML patients.

Additional file 3:

 Table S3. Cox regression univariate and multivariate analysis of variables for disease free survival in AML patients.

Additional file 4:

 Table S4. Different expressed genes/miRNAs between low and high ID3 expression groups.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhao, Q., Wang, Y., Yu, D. et al. Comprehensive analysis of ID genes reveals the clinical and prognostic value of ID3 expression in acute myeloid leukemia using bioinformatics identification and experimental validation. BMC Cancer 22, 1229 (2022). https://doi.org/10.1186/s12885-022-10352-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12885-022-10352-6

Keywords

  • AML
  • Expression
  • ID
  • ID3
  • Prognosis

BMC Cancer

ISSN: 1471-2407

Contact us